Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa